Strata Skin Sciences Inc.
Our Company Overview We are a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Our products include the XTRAC line of excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
$0.00
+$0.00 (+0.00%)
Price from 2 days ago
The business is unprofitable at the operating level (-15.31% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$4M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$31M
Net Income (TTM)
-$6M
Op. Margin
-15.31%
ROIC
-18.30%
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
Op. Cash Flow (TTM)
-$3M
Net Debt
$8M
Cash & Equiv.
$8M
3Y CAGR: -5.3%
Continue Research
SourceComputed from the 10-K filed 16 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 21 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Strata Skin Sciences (SSKN) overvalued?
Strata Skin Sciences (SSKN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Strata Skin Sciences scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Strata Skin Sciences a high-quality business?+
Strata Skin Sciences scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -15.3% operating margin and a -18.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Strata Skin Sciences a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh SSKN's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong? Check it in SSKN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SSKN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.